Prostate cancer vaccine - NewLink Genetics

Drug Profile

Prostate cancer vaccine - NewLink Genetics

Alternative Names: HyperAcute Prostate

Latest Information Update: 19 Dec 2012

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator NewLink Genetics Corporation
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Suspended Prostate cancer

Most Recent Events

  • 13 Dec 2012 Final efficacy, adverse events, pharmacodynamics and immunogenicity data from a phase I/II trial in Prostate cancer released by NewLink Genetics Corporation
  • 22 May 2008 Immunogenicity data from a phase I/II trial in hormone-refractory Prostate cancer presented at the 103rd Annual Meeting of the American Urological Association (AUA-2008)
  • 31 Mar 2005 Phase-I/II clinical trials in Prostate cancer in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top